Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Marjut Jaakkola"'
Autor:
Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, João Santos, Riikka Havunen, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Marjut Jaakkola, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Claudia Kistler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a0e17f652b7e484eace4f6c9324cd603
Autor:
Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, João Santos, Riikka Havunen, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Claudia Kistler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/218c591c834f4171bd71d0925ee0f06c
Autor:
Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, João Santos, Riikka Havunen, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Lyna Haybout, Claudia Kistler, Tatiana V Kudling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/1f633663a565450fb4194f6a12ab26d2
Autor:
Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, Riikka Havunen, João Manuel Santos, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Marjut Jaakkola, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Claudia Kistler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b336af2792464f85b3e5fe41c1798abe
Autor:
Marco Donia, Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, João Santos, Riikka Havunen, Eva Ellebaek, Brigitte Dreno, Inge Svane, Amir Khammari, Juha Kononen, Jorma Sormunen, Katriina Peltola, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Tine Monberg, Suvi Sorsa, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Claudia Kistler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ed04df0143f14f68bb949c0859f0b991
Autor:
Hanna Karhapää, Siru Mäkelä, Hanna Laurén, Marjut Jaakkola, Camilla Schalin-Jäntti, Micaela Hernberg
Publikováno v:
Endocrine Connections, Vol 11, Iss 2, Pp 1-11 (2022)
Objective: Immune checkpoint inhibitors (ICI) can cause endocrine adverse events. However, endocrine adverse events (AEs). However, endocrine AEs could be related to better treatment outcomes. Our aim was to investigate whether this holds true in a r
Externí odkaz:
https://doaj.org/article/6ba273ba1e7843ac92c279019c19eb0b
Autor:
Mariana Cázares-Olivera, Dominika Miroszewska, Lili Hu, Jacek Kowalski, Ulla-Marjut Jaakkola, Seppo Salminen, Bin Li, Emrah Yatkin, Zhi Chen
Publikováno v:
Exp Biol Med (Maywood)
Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders of the gastrointestinal tract with worldwide increasing incidence. Recent studies indicate that certain species of intestinal bacteria are strongly associated with IBD. Hel
Autor:
Victor Cervera-Carrascon, Inge Svane, Katriina Peltola, Tuomo Alanko, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Jorma Sormunen, Juha Kononen, Eva Ellebaek Steensgaard, Tine Monberg, Marco Donia, Amir Khammari, Brigitte Dreno, Joao Santos, Suvi Sorsa, Riikka Havunen, Akseli Hemminki
Publikováno v:
Regular and Young Investigator Award Abstracts.
Publikováno v:
Laboratory Animals
Regardless of the microbiological status of an animal facility, research animals may experience health problems, leading to pain, suffering and distress. Simple and efficient tools are needed to collect data systematically, allowing researchers to re
Although new compounds have improved the treatment landscape of metastatic melanoma, very limited data exist on the efficacy and safety of treating older patients with novel agents. Here, we provide results of BRAF (BRAFi) +/- MEK (MEKi) inhibitor tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c46a54e269659368f1a3158316b0bbc1
http://hdl.handle.net/10138/343795
http://hdl.handle.net/10138/343795